In vitro neurology assays

Screen your lead candidate compounds using InnoSer’s in vitro neurology assays to progress to preclinical in vivo studies with confidence

Home » Neurology CRO Services » In vitro neurology assays

InnoSer’s Neurodegenerative in vitro Assays CRO Services: 

In vitro neurology assays are carried out using primary and/or immortalized rodent and/or human (co)-cultures to screen and identify candidate compounds for further lead selection via preclinical in vivo research. Cultures of cells found within the central nervous system (CNS) such as microglial and neuronal cells allow you to evaluate the mechanism of action and efficacy of your novel investigational compounds in an in vitro setting for neurotoxicity, neurodegeneration/neuroprotection or neuroinflammation assessment. 

InnoSer offers preclinical contract research services using a wide range of commercially available cell lines, primary rodent cells as well as ex vivo brain slices. Leverage our validated in vitro neurodegeneration assays or partner with our scientists to set up and validate custom assays. After an initial disease model induction phase (using disease-associated proteins, protein aggregates. and chemical toxins), cell cultures are treated with your novel investigational compounds of choice to determine efficacy. In vitro neurodegenerative disease assays can be performed before or in conjunction with running in vivo preclinical studies (PK/PD profiling or efficacy studies in InnoSer’s mouse models of neurodegenerative diseases).  

✓  Wide range of neurology in vitro assays in (co)-cultures of rodent primary cells e.g., ex vivo brain slides, and immortalized rodent and human cell lines of neuronal and microglial cells (e.g. SHSY5Y, HCM3). 

✓  Neurodegenerative disease-associated proteins, chemical induction of disease phenotype, or transgenic cell lines.

✓  Wide range of assays (e.g., aggregation, phagocytosis, neurotoxicity, and neuroinflammation) 

✓ Custom model and assay validation services available. 

placing 96-well plate under microscope for live cell imaging

Developing new, safe, and efficacious therapies is an extremely intricate process. As a preclinical neurology contract research organization (CRO), InnoSer partners with you to help you navigate the complexities of this research area.  

Take advantage of InnoSer’s collaborative approach to develop the most optimal study design. With flexible and fast study start times you can perform your research at an accelerated pace. By outsourcing your preclinical neurology studies to InnoSer, you gain access to our in vitro and in vivo neurology drug development portfolio.  

Your Neurology Research Starts Here.

Choose the Right Model for Your Research with Confidence

Belgian based preclinical neurology CRO mouse models

Example data featuring in vitro neurology assays:

In vitro neurology assays

Key in vitro neurology assays that InnoSer offers:


Test the efficacy of your treatments using one of following in vitro assays:

  • Neuroinflammation 
  • Phagocytosis assay 
  • Aggregation assay
  • Neurotoxicity/ cell viability assay
  • Live cell imaging (IncuCyte)  
  • Immunocytochemistry 
  • Analysis of NO, ROS, cytokines 
  • MSD or ELISA panels (Aβ38, Aβ40, Aβ42, APP, α-Synuclein Contactin-2/TAG-1, Neprilysin, Neuronal pentraxin-1, Tau) 
Neurodegenerative disease in vitro modelling

Model neurodegenerative diseases using the following methods: 
 
  • Disease-related peptides (e.g., amyloid-β fibrils, MBP, α-synuclein, etc.)
  • Stimulus–induced (e.g., LPS, IL-13, Rotenone, etc.)
  • Neurotoxins (e.g., H2O2, 6-OHDA, Rotenone, etc.) 

      The People Behind Your Research

      Jolien Beekens, PhD

      Jolien Beekens, PhD, In Vitro Neurology Study Director

      With in vitro screening methods available as a suited first step in your development process our team of experts have the experience to optimise your study design process.

      Thomas Vogels, PhD Neurology study director InnoSer

      Thomas Vogels, PhD, In Vivo Neurology Study Director

      Leads an expert team of scientists with vast experience in our Neurology models to help you choose the right model and guide your optimal study design. We provide the solution to accelerating your drug development.

      Stay Curious: More Articles to Explore

      MDX Mouse Model Validation Data

      MDX Mouse Model Validation Data

      This month we’re highlighting one of the most commonly used mouse models to study Duchenne Muscular Dystrophy (DMD) – the MDX mouse model B10.mdx), and explore how our advanced services can support your efficacy studies in DMD.   The X-linked muscular dystrophy (MDX)...

      Phenotyping of a C3-PMP22 mouse model of CMT1A 

      Phenotyping of a C3-PMP22 mouse model of CMT1A 

      Charcot-Marie Tooth (CMT) disease is a hereditary, demyelinating peripheral neuropathy, leading to progressive muscle atrophy, weakness and subsequent walking disabilities and sensory impairments. Charcot-Marie Tooth Type 1A (CMT1A) is the most common type of CMT,...

      AAALAC Accreditation

      InnoSer has earned the AAALAC accreditation, demonstrating our commitment to responsible animal care and use. AAALAC International is a nonprofit organization that promotes the humane treatment of animals in science through voluntary accreditation and assessment programs. Our accreditation is valid for three years, incl. 2023. Read more about the AAALAC accreditation programme here.

      AAALAC logo

      Animal Welfare

      The 3Rs impact everything from policy and regulatory change to the development and uptake of new technologies and approaches. This is why InnoSer has ongoing commitment and monitoring of these processes. The steps we practice maximize our ability to replace, reduce and refine animal involvement and facilitate our commitment to these principles when it comes to research and drug development.